卡米丹卢马布特西林治疗复发性或耐火性经典霍奇金淋巴瘤:一项第二阶段研究
Alex F Herrera1, Stephen M Ansell2, Pier Luigi Zinzani3
1City of Hope, Duarte, California, United States.
Blood advances
|August 14, 2025
概括
卡米丹卢马布特西林 (Cami) 在治疗复发性/耐药性经典霍奇金淋巴瘤 (cHL) 中表现出显著的疗效. 然而,严重的不良事件限制了其在重度预治疗患者的使用.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 经典霍奇金淋巴瘤 (cHL) 结果正在改善,但对于复发或耐药病例需要新的治疗方法.
- 在布伦图西马布维多丁/PD-1 抑制剂治疗后复发/耐药性cHL的患者需要新的治疗选择.
研究的目的:
- 评估卡米丹卢马布特西林 (Cami) 的疗效和安全性,这是一种抗CD25抗体-药物结合体,在复发/耐药cHL的患者中.
- 评估Cami治疗的整体反应率 (ORR),完全反应率 (CRR),无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 第2期研究 (ADCT-301-201) 涉及117名患有复发性/耐药性cHL的成年患者,这些患者先前接受过治疗.
- 患者在1-2周期内静脉注射45微克/千克的卡米,然后每3周服用30微克/千克,长达1年.
主要成果:
- 该ORR为70.1% (95%CI,60.9-78.2%),其CRR为33.3% (24.9-42.6%). 在此基础上,该ORR为37.1% (95%CI,60.9-78.2%),其CRR为33.3% (24.9-42.6%).
- 中位数的PFS为9.13个月 (95% CI,5.3-15-0);中位数的OS没有达到.
- 由于不良事件导致的治疗中止发生在28.2%的患者中,皮肤和神经系统疾病很常见.
结论:
- 卡米丹卢马布特西林在重度预治疗的复发性/耐火性cHL中表现出有效性.
- 该药物的安全性概况,包括诸如吉兰-巴雷综合征之类的严重不良事件,对临床使用提出了重大挑战.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203


